Skip to main content
Equibles

PRFX · PRF Technologies Ltd.

Track PRFX — free

Use PRFX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRFX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.74 +0.03 (+3.90%)
Rebalance outlook locked
Market Cap
$2.49M
Shares
3.50M
Volume · Oct 20 15.61K Avg daily vol (3M) 281.86K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.72 Open$0.75 Day$0.72–0.78 52W close$0.71–6.60 Avg vol 30d261K Short int28K · 0.8% float · 1.0d Short vol6% DataSep 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$31,000
Trailing 12 months
Net income (TTM)
−$5.65M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-17,077.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-161.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+368.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.8%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −63%
below
Price vs 50-day avg −23%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −22%
trailing
6-month return −61%
trailing
YTD return −77%
this year
Relative strength −70%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+100% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.79% of float · ▼ -59.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
8 holders — near 3-yr high, broad support
Squeeze score 26
low risk · 0–100
Fundamentals
Strong
EPS growth +93%
Y/Y
Free cash flow $-4.0M
Balance sheet $3.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 180%
annualized · 1-yr
Max drawdown −89%
past year
ATR 9.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−63% Bearish
Price vs 50-day avg
−23% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+100% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.79% of float · ▼ -59.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
8 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $7
vs 200-day avg -63% vs 50-day avg -23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRFX
PRF Technologies Ltd.
this stock
$2.49M — — — 0.8%
TAK
Takeda Pharmaceutical Co Ltd
 $62.65B +28.8% — — 0.1%
GALDY
Galderma Group AG/ADR
 $48.90B +1.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $48.14B +30.9% +4.3% 67.7 2.6%
HLN
Haleon plc
 $44.59B +0.6% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
8
% held
5.8%
Net QoQ
+187.8K sh
Top holder
Yorkville Advisors Global…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
27.6K
Days to cover
1.0d
Change
-40.9K sh
View
Short Volume
Short vol %
6%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
4.8K
Value
$4.7K
As of
Sep 28, 2026
View
Off-Exchange
Off-exchange %
68.6%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$17.0K
Net income (FY)
$-5.0M
EPS diluted
$-7.47
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 28, 2026
This year
29
View
Exempt Offerings
Offering
$6.0M
Filed
Mar 19, 2021
View

Performance

5D 20D 120D MTD YTD
PRFX -11.4% -22.1% -61.5% -23.8% -77.4%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -10.3% -21.6% -69.5% -24.6% -90.2%
Key facts CIK 1801834 CUSIP M77798201 Visit website Investor relations